HEL · ORNBV.HE
Orion Oyj
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
Loading market information…
HEL · BIOBV.HE · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:24 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Biohit Oyj’s quoted price sits in the lower half of its reported 52-week range, 44.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Biohit Oyj’s forward annual dividend is €0.72 per share, paid annual. The forward yield is 34.28% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Biohit Oyj’s next earnings report is currently expected on Feb 17, 2027, with estimated earnings per share of €0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biohit Oyj’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:52 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 14, 2024 |
| €0.03+65.4% vs estimate |
| €6.60M+11.86% vs estimate |
| Q2 2023 | Aug 9, 2023 | €0.09+85.68% vs estimate | €6.50M+12.07% vs estimate |
|---|
| Q4 2022 | Dec 31, 2022 | -€0.02 | €4.80M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
€38.60-€1.10 (-2.77%)
Bittium Oyj’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
€6.04+€0.03 (+0.5%)
Terveystalo Oyj’s quoted price sits in the lower half of its reported 52-week range, 42.03% below the high.
€10.38-€0.02 (-0.19%)
Revenio Group Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.15% below the high.
€6.05-€0.12 (-1.94%)
Tecnotree Oyj’s quoted price sits in the upper half of its reported 52-week range, 24.28% below the high.
€1.90-€0.08 (-3.85%)
SSH Communications Security Oyj’s quoted price sits in the lower half of its reported 52-week range, 50.78% below the high.
€0.23-€0.00 (-1.68%)
Afarak Group Oyj’s quoted price sits in the lower half of its reported 52-week range, 54.47% below the high.
€0.07€0.00 (0.0%)
Dovre Group Plc’s quoted price sits in the lower half of its reported 52-week range, 79.61% below the high.
